Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability | Zendy

Shinsuke Nakamura | Zendy; Tetsuro Noguchi | Zendy; Yuki Inoue | Zendy; Shuji Sakurai | Zendy; Anri Nishinaka | Zendy; Yoshifumi Hida | Zendy; Tomomi Masuda | Zendy; Yasuhiro Nakagami | Zendy; Naoto Horai | Zendy; Hideshi Tsusaki | Zendy; Hideaki Hara | Zendy; Masamitsu Shimazawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability

Author(s) -

Shinsuke Nakamura,

Tetsuro Noguchi,

Yuki Inoue,

Shuji Sakurai,

Anri Nishinaka,

Yoshifumi Hida,

Tomomi Masuda,

Yasuhiro Nakagami,

Naoto Horai,

Hideshi Tsusaki,

Hideaki Hara,

Masamitsu Shimazawa

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-25745

Subject(s) - pathological , activator (genetics) , angiogenesis , medicine , cancer research , pathology , receptor

Ocular angiogenesis, including retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration, are closely related to oxidative stress. Many reports have shown that the cellular protective mechanism against oxidative stress and inflammatory response has nuclear factor-erythroid 2-related factor-2 (Nrf2) activity. The aim of this study was to investigate the effectiveness and mechanism of Nrf2 activation in treating the ocular diseases with abnormal vessels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research